|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.050 USD | +1.80% |
|
+2.84% | -60.26% |
| 07-08 | Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation | RE |
| 07-08 | Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn | CI |
Company Valuation: Quoin Pharmaceuticals, Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.19 | 6.883 | 4.842 | 5.328 | 5.229 | - | - |
| Change | - | -54.69% | -29.65% | 10.02% | -1.85% | - | - |
| Enterprise Value (EV) | 15.19 | 6.883 | 4.842 | 5.328 | 5.229 | 5.229 | 5.229 |
| Change | - | -54.69% | -29.65% | 10.02% | -1.85% | 0% | 0% |
| P/E ratio | -0.34x | -0.36x | -0.51x | -0.34x | -0.33x | -0.57x | -3.69x |
| PBR | - | - | - | - | - | - | - |
| PEG | -0x | 0x | 0x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | 0.8x | 0.09x |
| EV / Revenue | - | - | - | - | - | 0.8x | 0.09x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0.32x | -0.55x | 0.19x |
| EV / FCF | -3.28x | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -28,455 | -1,638 | -337.4 | -66.85 | -27.3 | -15.75 | -2.45 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 6.528 | 56.97 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -6.063 | -9.258 | -9.378 | -9.528 | -16.5 | -9.51 | 28.18 |
| Net income 1 | -21.46 | -9.447 | -8.687 | -8.962 | -16.05 | -10.52 | -1.699 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 9,555.015 | 596.401 | 171.675 | 22.775 | 9.050 | 9.050 | 9.050 |
| Nbr of stocks (in thousands) | 1.59 | 11.5 | 28.2 | 234 | 588.2 | - | - |
| Announcement Date | 14/04/22 | 09/03/23 | 13/03/24 | 13/03/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.33x | - | - | - | 5.23M | ||
| 39.05x | 5.68x | 19.89x | 0.87% | 50.02B | ||
| 156.36x | 5.39x | 92.41x | -.--% | 29.65B | ||
| 46.55x | 9.41x | 28.13x | 0.4% | 28.69B | ||
| 21.78x | 2.53x | 10.73x | -.--% | 28.16B | ||
| 23.83x | 1.96x | 8.86x | 1.09% | 12.7B | ||
| 16.11x | 1.83x | 9.19x | -.--% | 11.96B | ||
| -42.19x | 14.87x | -56.47x | -.--% | 10.59B | ||
| 25.41x | 5.24x | 13.91x | 0.1% | 10.42B | ||
| -37.48x | 8.35x | 2028.67x | -.--% | 9.85B | ||
| Average | 24.91x | 6.14x | 239.48x | 0.27% | 19.21B | |
| Weighted average by Cap. | 44.17x | 5.86x | 128.03x | 0.36% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- QNRX Stock
- Valuation Quoin Pharmaceuticals, Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition